Hiippala ST - Search Results

1

Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates.

Hiippala ST, Myllylä GJ, Vahtera EM. Hiippala ST, et al. Anesth Analg. 1995 Aug;81(2):360-5. doi: 10.1097/00000539-199508000-00026. Anesth Analg. 1995. PMID: 7542432

2

Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.

Hiippala ST, Strid LJ, Wennerstrand MI, Arvela JV, Niemelä HM, Mäntylä SK, Kuisma RP, Ylinen JE. Hiippala ST, et al. Anesth Analg. 1997 Apr;84(4):839-44. doi: 10.1097/00000539-199704000-00026. Anesth Analg. 1997. PMID: 9085968 Clinical Trial.

3

Dextran and hydroxyethyl starch interfere with fibrinogen assays.

Hiippala ST. Hiippala ST. Blood Coagul Fibrinolysis. 1995 Dec;6(8):743-6. Blood Coagul Fibrinolysis. 1995. PMID: 8825225

4

Relation of Use of Red Blood Cell Transfusion After Acute Coronary Syndrome to Long-Term Mortality.

Allonen J, Nieminen MS, Hiippala S, Sinisalo J. Allonen J, et al. Am J Cardiol. 2018 Jun 15;121(12):1496-1504. doi: 10.1016/j.amjcard.2018.02.035. Epub 2018 Mar 13. Am J Cardiol. 2018. PMID: 29631802

5

Perioperative volume effect of HES 120/0.7 compared with dextran 70 and Ringer acetate.

Hiippala S, Teppo AM. Hiippala S, et al. Ann Chir Gynaecol. 1996;85(4):333-9. Ann Chir Gynaecol. 1996. PMID: 9014063 Clinical Trial.

6

Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty.

Hiippala S, Strid L, Wennerstrand M, Arvela V, Mäntylä S, Ylinen J, Niemelä H. Hiippala S, et al. Br J Anaesth. 1995 May;74(5):534-7. doi: 10.1093/bja/74.5.534. Br J Anaesth. 1995. PMID: 7772427 Clinical Trial.

7

Albumin, HES 120 and dextran 70 as adjuvants to red blood cell concentrates: a study on colloid osmotic pressure changes in vitro.

Hiippala S, Linko K, Myllylä G, Lalla M, Mäkeläinen A. Hiippala S, et al. Acta Anaesthesiol Scand. 1991 Oct;35(7):654-9. doi: 10.1111/j.1399-6576.1991.tb03367.x. Acta Anaesthesiol Scand. 1991. PMID: 1723826

8

Replacement of major surgical blood loss by hypo-oncotic or conventional plasma substitutes.

Hiippala S, Linko K, Myllylä G, Lalla M, Hekali R, Mäkeläinen A. Hiippala S, et al. Acta Anaesthesiol Scand. 1995 Feb;39(2):228-35. doi: 10.1111/j.1399-6576.1995.tb04049.x. Acta Anaesthesiol Scand. 1995. PMID: 7540789 Clinical Trial.

9

Replacement of massive blood loss.

Hiippala S. Hiippala S. Vox Sang. 1998;74 Suppl 2:399-407. doi: 10.1111/j.1423-0410.1998.tb05449.x. Vox Sang. 1998. PMID: 9704474 Review.

10

Massive blood transfusion exceeding 50 units of plasma poor red cells or whole blood: the survival rate and the occurrence of leukopenia and acidosis.

Hakala P, Hiippala S, Syrjälä M, Randell T. Hakala P, et al. Injury. 1999 Nov;30(9):619-22. doi: 10.1016/s0020-1383(99)00166-7. Injury. 1999. PMID: 10707230

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results